CClinicalTrials.gg
CompletedNCT02376205Updated Feb 13, 2020

Anesthetic to Reduce Dysphagia After Anterior Cervical Discectomy and Fusion Surgery

An interventional study of bupivacaine hydrochloride 0.5% solution and 0.9% NaCl solution in Dysphagia, sponsored by Justin Parker Neurological Institute. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-02-13.

Sponsored by Justin Parker Neurological Institute · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The main objective of this study is to analyze the effects of local anesthetic application into the retropharyngeal space and its ability to reduce dysphagia symptoms and/or occurrence rates in patients undergoing anterior cervical discectomy and fusion.

Read the detailed description

The patients will be randomly assigned into one of the two groups to receive either bupivacaine hydrochloride 0.5% solution if they are randomized to the treatment group or 0.9% NaCl solution if they are randomized to the control group. These solutions will be poured into the retropharyngeal space intraoperatively before wound closure.

02

Conditions studied

  • Dysphagia

Browse trials for

Keywords

  • Anterior Cervical Discectomy and Fusion
  • Dysphagia
03

In context

Deglutition Disorders

710 studies on the registry are indexed under Deglutition Disorders; 219 are open to participants now.

This study's enrollment of 150 is above the median of 60 across 471 interventional studies indexed under Deglutition Disorders.

Browse Deglutition Disorders studies →

Lead sponsor

Justin Parker Neurological Institute is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients older than 18 y.o.
  • Patients undergoing one- or two-level anterior cervical discectomy and fusion surgery for radiculopathy or myelopathy symptoms
  • Patients are wiling and able to sign informed consent and complete questionnaires

Exclusion criteria

Exclusion Criteria:

  • More than 2-level ACDF surgeries
  • Previous cervical spine surgery
  • Surgeries for trauma, infection or tumor
  • Known hypersensitivity reactions to bupivacaine hydrochloride or other amino-amide anesthetics (e.g. lidocaine)
  • Known history of swallowing issues (e.g. dysphagia, odynophagia)
  • Pregnant or breastfeeding
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Double (Participant, Investigator)
Enrollment
150 participants (actual)

Study arms

  • Experimental
    bupivacaine hydrochloride 0.5% solution

    Bupivacaine hydrochloride 0.5% 10 mL solution poured into the retropharyngeal space intraoperatively before wound closure during anterior cervical discectomy and fusion procedure

    Drug: bupivacaine hydrochloride 0.5% solution

  • Placebo comparator
    0.9% NaCl solution

    0.9% NaCl 10 mL solution poured into the retropharyngeal space intraoperatively before wound closureduring anterior cervical discectomy and fusion procedure

    Drug: 0.9% NaCl solution

Interventions

  • Drugbupivacaine hydrochloride 0.5% solution

    10mL will be poured into the retropharyngeal space intraoperatively during anterior cervical discectomy and fusion procedure

    Also known as: Marcaine

  • Drug0.9% NaCl solution

    10mL will be poured into the retropharyngeal space intraoperatively during anterior cervical discectomy and fusion procedure

    Also known as: Saline

06

What researchers measure

Primary outcomes

  1. Reduction in dysphagia scores

    Swallowing-Quality of Life Questionnaire

    Time frame: 3 months

07

Study locations

1 site
  • Boulder Neurosurgical Associates
    Boulder, Colorado 80303, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 13, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02376205
Lead sponsor
Justin Parker Neurological Institute
Responsible party
Sponsor
First posted
Mar 3, 2015
Start date
Feb 2015
Primary completion
Mar 11, 2019
Completion
Mar 11, 2019
Last update
Feb 13, 2020

Study contacts

Alexander Mason, MD
principal investigator · Boulder Neurosurgical Associates

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion